Thus, these findings may provide a rationale for future studies to test the combined blockade of PD-1, TIM-3, and VISTA, to improve the persistence and functions of tumor-reactive PD-1+ TIM-3+ CTLs. Here, PDCD1 is linked to neoplasm.